Showing results (181-190 of 310) with videos related to
Sort By:
Pageof 31
Journal of Medicinal Chemistry|November 22, 1996
Diastereoselective synthesis of all four isomers of 3-(4-chlorophenyl) glutamic acid: identification of the isomers responsible for the potentiation of L-homocysteic acid-evoked depolarizations in neonatal rat motoneuronsD E Jane, D J Chalmers, J A Howard, et al.Pharmaceutical Research|June 19, 2001
Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administrationD Y Mitchell, W H Barr, R A Eusebio, et al.Antimicrobial Agents and Chemotherapy|January 1, 1992
Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteersJ A Smithers, H K Kulmala, G A Thompson, et al.Journal of Clinical Pharmacology|March 10, 2000
Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteersD Y Mitchell, R A Eusebio, N A Sacco-Gibson, et al.British Journal of Clinical Pharmacology|March 16, 2000
Effect of renal function on risedronate pharmacokinetics after a single oral doseD Y Mitchell, J V St Peter, R A Eusebio, et al.PLOS Mental Health|February 9, 2026
Depression and its associated factors among people living with HIV in the Volta region of GhanaJerry John Nutor, Robert Kaba Alhassan, Rachel G A Thompson, et al.AIDS Research and Therapy|June 29, 2023
Influence of depression and interpersonal support on adherence to antiretroviral therapy among people living with HIVJerry John Nutor, Akua O Gyamerah, Robert Kaba Alhassan, et al.Journal of Pharmaceutical Sciences|November 1, 1996
Assessment of doxylamine influence on mixed function oxidase activity upon multiple dose oral administration to normal volunteersG A Thompson, J V St Peter, M A Heise, et al.Biopharmaceutics & Drug Disposition|November 1, 1992
Applicability of teicoplanin dosage adjustment guidelines for renally impaired patients over the range of 3 to 30 mg kg-1J A Smithers, G A Thompson, M T Kenny, et al.Alimentary Pharmacology & Therapeutics|October 26, 2016
Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosisS A Harrison, S R Marri, N Chalasani, et al.Pageof 31